{"results":[{"description":"The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.","format":"press_release","link":"/government/news/semaglutide-wegovy-approved-to-treat-form-of-liver-disease","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-07-03T14:25:57Z","title":"Semaglutide (Wegovy) approved to treat form of liver disease","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.098182246,"_id":"/government/news/semaglutide-wegovy-approved-to-treat-form-of-liver-disease","elasticsearch_type":"edition","document_type":"edition"},{"description":"MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.","format":"press_release","link":"/government/news/mhra-updates-guidance-for-semaglutide-prescribers-and-patients","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-02-05T15:13:34Z","title":"MHRA updates guidance for semaglutide prescribers and patients","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.09557962,"_id":"/government/news/mhra-updates-guidance-for-semaglutide-prescribers-and-patients","elasticsearch_type":"edition","document_type":"edition"},{"description":"Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management and cardiovascular risk reduction. Patients reporting a sudden loss of vision (including partial loss) while on semaglutide treatment should be urgently referred for ophthalmological examination.","format":"drug_safety_update","link":"/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-02-05T13:24:42Z","title":"Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.08594328,"_id":"/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease","format":"press_release","link":"/government/news/mhra-approves-glp-1-receptor-agonist-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2024-07-23T14:20:59Z","title":"MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.08128415,"_id":"/government/news/mhra-approves-glp-1-receptor-agonist-semaglutide-to-reduce-risk-of-serious-heart-problems-in-obese-or-overweight-adults","elasticsearch_type":"edition","document_type":"edition"},{"description":" No evidence of supply or harm to patients ","format":"news_story","link":"/government/news/falsified-ozempic-semaglutide-pens-identified-at-two-wholesalers-in-the-uk","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2023-10-17T23:00:00Z","title":"Falsified Ozempic (semaglutide) pens identified at two wholesalers in the UK","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.05701503,"_id":"/government/news/falsified-ozempic-semaglutide-pens-identified-at-two-wholesalers-in-the-uk","elasticsearch_type":"edition","document_type":"edition"},{"description":"There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, which have different stated mg doses but are bioequivalent, will both be available on the market. ","format":"drug_safety_update","link":"/drug-safety-update/rybelsus-r-semaglutide-tablets-transition-to-new-formulation-and-risk-of-medication-error","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2025-12-17T14:17:47Z","title":"Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.051889174,"_id":"/drug-safety-update/rybelsus-r-semaglutide-tablets-transition-to-new-formulation-and-risk-of-medication-error","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK. ","format":"drug_safety_update","link":"/drug-safety-update/ozempicv-semaglutide-and-saxenda-liraglutide-vigilance-required-due-to-potentially-harmful-falsified-products","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2023-11-23T14:15:41Z","title":"Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products  ","topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.049981393,"_id":"/drug-safety-update/ozempicv-semaglutide-and-saxenda-liraglutide-vigilance-required-due-to-potentially-harmful-falsified-products","elasticsearch_type":"drug_safety_update","document_type":"drug_safety_update"},{"description":"Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. ","format":"press_release","link":"/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-06-11T15:03:39Z","title":"First GLP-1 tablet for weight loss approved in the UK","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.049545344,"_id":"/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk","elasticsearch_type":"edition","document_type":"edition"},{"description":"As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review.","format":"news_story","link":"/government/news/single-dose-72mg-semaglutide-wegovy-pen-approved-to-treat-adult-patients-with-obesity","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-04-14T08:32:36Z","title":"Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.049448382,"_id":"/government/news/single-dose-72mg-semaglutide-wegovy-pen-approved-to-treat-adult-patients-with-obesity","elasticsearch_type":"edition","document_type":"edition"},{"description":"The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.","format":"news_story","link":"/government/news/medicines-regulator-approves-up-to-72mg-dose-of-semaglutidewegovy-for-patients-with-obesity-only","organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"public_timestamp":"2026-01-16T08:27:16Z","title":"Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only","world_locations":[],"topical_events":[],"organisation_content_ids":["240f72bd-9a4d-4f39-94d9-77235cadde8e"],"expanded_organisations":[{"organisation_type":"executive_agency","organisation_state":"live","superseding_organisations":[],"acronym":"MHRA","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","link":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","parent_organisations":["department-of-health-and-social-care"],"superseded_organisations":[],"analytics_identifier":"EA63","title":"Medicines and Healthcare products Regulatory Agency","organisation_crest":"single-identity","organisation_brand":"department-of-health-social-care","child_organisations":[],"logo_formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","slug":"medicines-and-healthcare-products-regulatory-agency","public_timestamp":"2025-06-25T11:21:52Z"}],"index":"govuk","es_score":0.017154993,"_id":"/government/news/medicines-regulator-approves-up-to-72mg-dose-of-semaglutidewegovy-for-patients-with-obesity-only","elasticsearch_type":"edition","document_type":"edition"}],"total":41,"start":0,"aggregates":{},"suggested_queries":[],"suggested_autocomplete":[],"es_cluster":"A"}